

Aurobindo Pharma inks agreement with COVAXX for COVID-19 vaccine development

24 December 2020 | News

COVAXX's UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution



Hyderabad based Aurobindo Pharma Limited and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.

Commenting on the development, N. Govindarajan, Managing Director, Aurobindo Pharma Limited, said: "We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic."

Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets.

Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX's vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad.

Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021.